Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, announced today a restructuring of ...

Neupogen (Filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of neutrophils in patients with leukocyte disorders, particularly in those with ...

Eight percent of patients experienced febrile neutropenia. With the exception of one patient who experienced grade 4 adrenal insufficiency, endocrine immune-related side effects were all grade 1 (mild ...

"We expect this organizational redesign to sharpen our focus on the execution of our ongoing global pivotal Phase 3 clinical trial of mavorixafor in chronic neutropenia while we continue to build WHIM ...

[89] The beneficial effect of the treatment is associated with a reduction in serum levels of IL-1β and TNF-α and, occasionally, with amelioration of neutropenia substantiating the important ...

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August.

Your immune system includes your body's cells, tissues, and organs, which work together to fight off infections and diseases. But how much do you know about it? When you understand everything that ...